Summary - Funding Rounds

Founding Date

2013

Total Funding

$310 m

Investors

In total, Juno Therapeutics had raised $310 m. Juno Therapeutics is a subsidiary of Celgene

Juno Therapeutics Income Statement

Juno Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

252.4m187.9m232.8m

Accounts Receivable

315.0k13.3m13.9m

Prepaid Expenses

13.3m

Inventories

8.4m26.5m

Current Assets

951.8m772.3m753.4m

PP&E

42.1m81.7m133.1m

Goodwill

122.1m221.3m221.3m

Total Assets

1.4b1.3b1.4b

Accounts Payable

4.2m4.4m12.4m

Current Liabilities

119.7m114.9m208.8m

Long-term debt

9.9m

Total Debt

9.9m

Common Stock

12.0k

Preferred Stock

Additional Paid-in Capital

1.7b1.9b2.3b

Retained Earnings

(585.7m)(831.2m)(1.3b)

Total Equity

1.1b1.1b1.0b

Financial Leverage

1.3 x1.3 x1.4 x

Juno Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(51.8m)(245.6m)(437.1m)

Depreciation and Amortization

2.0k14.2m23.6m

Accounts Receivable

33.0k(13.0m)(623.0k)

Accounts Payable

(2.7m)3.7m46.9m

Cash From Operating Activities

(103.6m)(189.8m)(225.0m)

Purchases of PP&E

(42.0k)(56.2m)(60.9m)

Cash From Investing Activities

(42.0k)88.6m(68.2m)

Cash From Financing Activities

66.5m36.8m338.2m

Net Change in Cash

44.9m

Juno Therapeutics Ratios

USDQ1, 2015

Financial Leverage

1.4 x

Juno Therapeutics Operating Metrics

FY, 2016

Patent Applications

481

Patents (Foreign)

86

Patents (US)

72

Juno Therapeutics Employee Rating

468 votes
Culture & Values
4.4
Work/Life Balance
3.7
Senior Management
3.7
Salary & Benefits
4
Career Opportunities
4
Source